Bio­gen has a shaky end to H1 with a $542M write-off adding to its woes — but an­a­lysts see big rev­enue ahead for Aduhelm

All eyes at Bio­gen’s Q2 earn­ings call Thurs­day were on Aduhelm, but in­vestors al­so got a glimpse of what Bio­gen would have faced had the FDA not opt­ed to ap­prove their con­tro­ver­sial Alzheimer’s drug.

That glimpse, re­veal­ing a com­bi­na­tion of de­clin­ing sales, grow­ing com­pe­ti­tion and failed med­i­cines, un­der­scores the stakes of the big biotech’s Aduhelm ef­forts, as ex­ecs punch back at the crit­i­cism they’ve en­gen­dered in the po­lit­i­cal and med­ical world and vig­or­ous­ly push­es its sales staff to roll out the drug as fast as pos­si­ble.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER